Total trials
65
Active
9
Phase 3
4
Total enrollment
5,714
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Meglumine antimoniate | — | — | — | — | 4 | ||
| Miltefosine | — | — | — | — | — | 1 | |
| Pentoxifylline | — | — | — | — | — | 1 |
Next readouts
- 2025-08
Top conditions
- Electrical Stimulation4
- Healthy4
- Aging3
- Low Back Pain3
- Radiodermatitis3
- Leprosy2
- Learning Process in Nursing Graduation2
- Visceral Leishmaniasis2
Frequently asked questions about University of Brasilia
- How many clinical trials does University of Brasilia have on ClinicalTrials.gov?
- University of Brasilia is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Brasilia's trials are in Phase 3?
- 4 of University of Brasilia's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Brasilia focus on?
- University of Brasilia's most-studied conditions on ClinicalTrials.gov are Electrical Stimulation, Healthy, Aging, Low Back Pain, Radiodermatitis.
- When are University of Brasilia's next clinical trial readouts?
- University of Brasilia has 1 upcoming primary-completion readout tracked here; the soonest is “The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil”, expected around 2025-08.